Treatment of asymptomatic @entity358 in immunocompetent hosts with oral XXXX .

@entity1 @entity358 @entity2380
BACKGROUND: @entity358 is occasionally detected on routine imaging studies in healthy hosts with no or mild symptoms. Isolated @entity358 may be observed without specific therapy in asymptomatic immunocompetent hosts. However, considering that dissemination from a @entity358 can occur in @entity1 with no immunologic defects, treatment of asymptomatic @entity358 in immunocompetent hosts remains controversial. The aim of this study was to determine the role of @entity2380 therapy in the management of isolated @entity358 in asymptomatic healthy hosts. METHODS: We retrospectively analyzed the medical records and radiographic findings of 10 healthy subjects with isolated @entity358 diagnosed incidentally and treated with oral @entity2380 . RESULTS: All @entity1 had no respiratory or constitutional symptoms. The most common radiological findings were pulmonary nodules, and the number of nodules in each @entity1 was from 1 to 9. After histological confirmation, all @entity1 were treated with oral @entity2380 at a dosage of 400 mg per day for a median period of 6.4 months. No @entity1 developed an adverse reaction to @entity2380 . The mean interval between the initiation of antifungal therapy and final radiological response was 8.3 months. Seven of the 10 @entity1 showed complete resolution, and the other 3 @entity1 were assessed as having partial resolution. During the average follow-up period of 11.9 months, all @entity1 showed a favourable outcome with no relapse. The overall cure rate was 70%. CONCLUSION: These results suggest that @entity2380 may be an attractive therapeutic option for asymptomatic @entity358 in immunocompetent hosts.
